Matthew Spitzer, PhD

Associate Professor
Otolaryngology
[email protected]
Research Description: 

The Spitzer Lab is working to develop our understanding of how the immune system coordinates its responses across the organism with an emphasis on tumor immunology. We combine methods in experimental immunology and cancer biology with computation to understand the modes in which the immune system can respond to tumors and to rationally initiate curative immune responses against cancer.

Primary Thematic Area: 
Immunology
Secondary Thematic Area: 
Cancer Biology & Cell Signaling
Research Summary: 
Systems approaches to understand immune responses, particularly to cancer
Mentorship Development: 

3/3/20    Promoting Student Mental Health:A Presentation and Discussion (Staff and Faculty)
11/10/20    Optimizing the Efficiency of Your Lab
12/8/20    Setting Expectations with a "Welcome to the Lab' Letter (Parts 1 and 2)

Websites

Publications: 

Author Correction: Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.

Nature medicine

Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R, Tenvooren I, Marquez DM, Cho NW, Carmi Y, Spitzer MH

The tumor microenvironment of benign and malignant salivary gland tumors.

Head & neck

Wai KC, Okholm TLH, Ha PK, Marquez DM, Tenvooren I, Jones KB, Spitzer MH

Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.

JCI insight

Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.

bioRxiv : the preprint server for biology

Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma.

Journal for immunotherapy of cancer

Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan S